Crohn's Disease (CD) FDA approvals, PDUFA dates and pipeline.
Updated Snapshot 20261116T222116ZBuilt
We track 2 Crohn's Disease (CD) drugs. No FDA approvals recorded yet.
Drugs
| Drug | Sponsor | Modality | Designations |
|---|---|---|---|
| Skyrizi® (risankizumab) | ABBV | antibody | — |
| vedolizumab iv (MLN0002) | TAK | — | — |
Upcoming catalysts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Sep to Dec 2027Quarter disclosed | vedolizumab iv (MLN0002) | TAK | Topline readout | Crohn's Disease (CD) | Scheduled | ClinicalTrials.gov |
| September 2027Month disclosed | vedolizumab iv (MLN0002) | TAK | Primary completion | Crohn's Disease (CD) | Scheduled | ClinicalTrials.gov |
| February 2028Month disclosed | Skyrizi® (risankizumab) | ABBV | Primary completion | Crohn's Disease (CD) | Scheduled | ClinicalTrials.gov |
| Feb to May 2028Quarter disclosed | Skyrizi® (risankizumab) | ABBV | Topline readout | Crohn's Disease (CD) | Scheduled | ClinicalTrials.gov |
Past catalysts and decisions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| August 13, 2026 | RINVOQ® (upadacitinib) | ABBV | Topline readout | Crohn's Disease (CD) | Completed | ClinicalTrials.gov |
| July 18, 2025 | RINVOQ® (upadacitinib) | ABBV | Primary completion | Crohn's Disease (CD) | Completed | ClinicalTrials.gov |
All indications · Approval rates by indication
Questions
What Crohn's Disease (CD) drugs have upcoming PDUFA dates?
None disclosed.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.